Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

被引：105

作者：

Marin, David ^{[1
]}

Hedgley, Corinne ^{[2
]}

Clark, Richard E. ^{[3
]}

Apperley, Jane ^{[1
]}

Foroni, Letizia ^{[1
]}

Milojkovic, Dragana ^{[1
]}

Pocock, Christopher ^{[4
]}

Goldman, John M. ^{[1
]}

O'Brien, Stephen ^{[2
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London W12 0NN, England

[2] Newcastle Univ, No Inst Canc Res, Dept Haematol, Newcastle Upon Tyne, Tyne & Wear, England

[3] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England

[4] E Kent Hosp Natl Hlth Serv Trust, Dept Haematol, Canterbury, Kent, England

来源：

BLOOD | 2012年 / 120卷 / 02期

关键词：

TYROSINE KINASE INHIBITORS; BCR-ABL; CYTOGENETIC RESPONSE; TRANSCRIPT LEVELS; IMATINIB; INTERFERON; THERAPY; FAILURE;

D O I：

10.1182/blood-2012-01-407486

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dasatinib is effective therapy for newly diagnosed patients with chronic myeloid leukemia, but not all patients respond well. We analyzed the outcome of patients treated with dasatinib as first-line therapy to identify patients who are more likely to fare poorly. The 8.6% of patients who at 3 months had a BCR-ABL1/ABL1 ratio > 10% had a significantly worse 2-year cumulative incidence of complete cytogenetic response (58.8% vs 96.6%, P < .001) and molecular responses than the remaining patients with a lower transcript levels. The predictive value of the 3-month transcript level could be improved using the dasatinib-specific transcript level cut-offs, namely, 2.2%, 0.92%, and 0.57% for complete cytogenetic response, 3 log and 4.5 log reductions in the transcript level, respectively. The study was registered at www.clinicaltrials.gov as #NCT01460693. (Blood. 2012;120(2):291-294)

引用

页码：291 / 294

页数：4

共 20 条

[1] Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis [J].

de Lavallade, Hugues ;

Apperley, Jane F. ;

Khorashad, Jamshid S. ;

Milojkovic, Dragana ;

Reid, Alistair G. ;

Bua, Marco ;

Szydlo, Richard ;

Olavarria, Eduardo ;

Kaeda, Jaspal ;

Goldman, John M. ;

Marin, David .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3358-3363

[2]

Domenech JM, 2011, ANALISIS SUPERVIVENC

[3] A proportional hazards model for the subdistribution of a competing risk [J].

Fine, JP ;

Gray, RJ .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509

[4] Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia [J].

Foroni, Letizia ;

Wilson, Gill ;

Gerrard, Gareth ;

Mason, Joanne ;

Grimwade, David ;

White, Helen E. ;

de Castro, David Gonzalez ;

Austin, Stephen ;

Awan, Abida ;

Burt, Emma ;

Clench, Tim ;

Farruggia, Joanna ;

Hancock, Jeremy ;

Irvine, Alexandra E. ;

Kizilors, Aytug ;

Langabeer, Stephen ;

Milner, Benedict J. ;

Nickless, Guillermina ;

Schuh, Anna ;

Sproul, Anne ;

Wang, Lihui ;

Wickham, Caroline ;

Cross, Nicholas C. P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (02) :179-190

[5] Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies [J].

Gerrard, Gareth ;

Mudge, Katherine ;

Stewart, Rebecca ;

Foskett, Pierre ;

Stevens, David ;

Khorashad, Jamshid S. ;

Szydlo, Richard ;

Rezvani, Katy ;

Marin, David ;

Reid, Alistair ;

Apperley, Jane ;

Goldman, John ;

Foroni, Letizia .

AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (03) :313-315

[6]

Gray R. J., 1998, ANN STAT, V16, P1140

[7]

Hanfstein B, 2010, BLOOD, V116, P360

[8] Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results [J].

Hughes, Timothy ;

Deininger, Michael ;

Hochhaus, Andreas ;

Branford, Susan ;

Radich, Jerald ;

Kaecla, Jaspal ;

Baccarani, Michele ;

Cortes, Jorge ;

Cross, Nicholas C. P. ;

Druker, Brian J. ;

Gabert, Jean ;

Grimwade, David ;

Hehlmann, Ruediger ;

Kamel-Reid, Suzanne ;

Lipton, Jeffrey H. ;

Longtine, Janina ;

Martinelli, Giovanni ;

Saglio, Giuseppe ;

Soverini, Simona ;

Stock, Wendy ;

Goldman, John M. .

BLOOD, 2006, 108 (01) :28-37

[9] Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) [J].

Hughes, Timothy P. ;

Hochhaus, Andreas ;

Branford, Susan ;

Mueller, Martin C. ;

Kaeda, Jaspal S. ;

Foroni, Letizia ;

Druker, Brian J. ;

Guilhot, Francois ;

Larson, Richard A. ;

O'Brien, Stephen G. ;

Rudoltz, Marc S. ;

Mone, Manisha ;

Wehrle, Elisabeth ;

Modur, Vijay ;

Goldman, John M. ;

Radich, Jerald P. .

BLOOD, 2010, 116 (19) :3758-3765

[10] Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed [J].

Ibrahim, Amr R. ;

Clark, Richard E. ;

Holyoake, Tessa L. ;

Byrne, Jenny ;

Shepherd, Pat ;

Apperley, Jane F. ;

Milojkovic, Dragana ;

Szydlo, Richard ;

Goldman, John ;

Marin, David .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (12) :1779-1782

← 1 2 →